| Ytd | ||
| 1y |
| Open | 0.37 | Prev Close | 0.36 | Low | 0.36 | High | 0.36 | Mkt Cap | 33.90M |
| Vol | 4.38M | Avg Vol | 773.88K | EPS | -0.80 | P/E | N/A | Forward P/E | -0.63 |
| Beta | 1.25 | Short Ratio | 9.52 | Inst. Own | 83.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.60 | 200-d Avg | 2.17 | 1yr Est | 7.00 |
ELEV News
https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c
https://www.bloomberg.com/news/articles/2025-06-16/senate-republicans-to-omit-medicare-advantage-cut
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
NEW YORK , June 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investiga
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
BOSTON , June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncolog
https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-t
https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-t
-- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeti
-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs acro
-- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentia
ELEV decides to stop developing its lead drug after disappointing data from an early-stage study eva
On Thursday, Elevation Oncology, Inc. ELEV elected to discontinue the development of EO-3021, a Clau
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payloa
-- Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combinati
BOSTON , Feb. 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncolo
-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combinat
Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in
-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – --
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting
BOSTON , Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncolo
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR obs
Elevation Oncology (ELEV) might move higher on growing optimism about its earnings prospects, which
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards
https://www.hhs.gov/about/news/2024/03/26/hhs-announces-savings-41-prescription-drugs-thanks-inflati
Shares of Aehr Test Systems (NASDAQ: AEHR) shares fell sharply in pre-market trading after the comp
Friday's session saw 225 companies set new 52-week lows.
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares rose 112.5% to $0.6801 in pre-mar
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it
Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursd
Gainers ThermoGenesis Holdings, Inc. (NASDAQ: THMO) shares jumped 80% to $3.7820 after the compa
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the co
During Friday's trading, 71 companies set new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.